FDA advisory panel gives thumbs-up to CBD epilepsy treatment

Women, minority execs show few gains in U.S. cannabis industry, according to the latest data from the MJBiz Diversity, Inclusion and Equity Report. Get your copy here.

A CBD treatment for epilepsy is closer to becoming the first cannabis medicine approved for the U.S. market.

A panel of government health advisers gave a unanimous recommendation Thursday to the U.S. Food and Drug Administration to approve Epidiolex, a CBD medicine for rare epilepsy conditions that don’t respond to other drugs.

The panel voted unanimously to recommend that the FDA approve Epidiolex after hearing presentations on the drug’s effectiveness and safety.

The recommendation doesn’t bind the agency to approving Epidiolex, but its recommendations carry serious weight.

The FDA has said it will issue a decision by late June.

(Click here to read the full story at Hemp Industry Daily.)